IonQ R&D increased by 30.8% to $125.74M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 214.7%, from $39.95M to $125.74M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 97.2% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.48M | $6.18M | $4.92M | $7.34M | $9.65M | $13.29M | $13.70M | $16.23M | $19.87M | $24.60M | $31.62M | $32.37M | $31.20M | $33.18M | $40.08M | $39.95M | $103.36M | $66.30M | $96.10M | $125.74M |
| QoQ Change | — | +12.8% | -20.4% | +49.2% | +31.5% | +37.7% | +3.0% | +18.5% | +22.4% | +23.8% | +28.5% | +2.4% | -3.6% | +6.3% | +20.8% | -0.3% | +158.7% | -35.9% | +44.9% | +30.8% |
| YoY Change | — | — | — | — | +76.2% | +115.1% | +178.5% | +121.2% | +105.8% | +85.1% | +130.9% | +99.4% | +57.0% | +34.9% | +26.7% | +23.4% | +231.2% | +99.8% | +139.8% | +214.7% |